Company / Gross Margin
UroGen Pharma Ltd. Gross Margin History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Gross Margin
88.7%
FY2025
5-year range
87.7% / 89.3%
FY2021-FY2025
Trend
+1.1%
vs FY2024
Sector context
#2 of 28
Health Care
What the data says
Among 28 Health Care companies, UroGen Pharma Ltd. is in the top 7% for gross margin. Gross Margin returned to growth in FY2025 after 2 years of decline, reaching 88.7%.
Based on SEC 10-K filings.
88.7% in FY2025 with a 5-year CAGR of -11.3%. Ranks 2nd among 28 companies in Health Care.
Remained stable around 88.7% over the past 2 years.
Health Care sector context is included.
Gross Margin over time
Growth rates
- 3-Year Change
- -0.6pp
- 5-Year Change
- -11.3pp
- 10-Year Change
- -
Sector benchmark
Top 7% in Health CareTop 7% of 28This company 88.7% Sector average 60.3%
▼
+47.0% above sector average
Key checks
Key Insights
- In FY2025, gross margin increased 1.1% year-over-year.
- Currently 28.4pp above the Health Care sector average.
- Peak gross margin was recorded in FY2020.
- Lowest gross margin in the period was in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.09 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Gross MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | 88.7% | +1.1% |
| FY2024 | 87.7% | -0.4% |
| FY2023 | 88.1% | -1.3% |
| FY2022 | 89.3% | +0.0% |
| FY2021 | 89.3% | -10.7% |
| FY2020 | 100.0% | +7.9% |
| FY2019 | 92.7% | +254.8% |
| FY2018 | -59.8% | -164.6% |
| FY2017 | 92.6% | -7.2% |
| FY2016 | 99.8% | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026